Literature DB >> 1718923

Experience with prostate-specific antigen in prostatic carcinoma.

I Romics1, D Bach.   

Abstract

A total of 71 prostatic tumour patients and 45 prostatic adenoma patients were tested for prostate-specific antigen (PSA), immunological prostatic acid phosphatase (PAP) concentration as well as serum prostatic phosphatase (SPP) and enzymic serum phosphatase. It was found among untreated patients that PSA showed the highest percentage of pathologic affection in each stage. PSA, on the evidence of clearance test in the initial days of therapy and after a follow-up period of several months, gave a good picture of the course that the disease had taken.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1718923     DOI： 10.1007/bf02583990

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


  10 in total

1.  [Tumor markers in urologic neoplasms].

Authors:  M Wirth; J W Grups; H Frohmüller
Journal:  Fortschr Med       Date:  1986-09-18

2.  An evaluation of the immunochemical measurement of prostatic acid phosphatase and prostatic specific antigen in carcinoma of the prostate.

Authors:  J K Siddall; E H Cooper; D W Newling; M R Robinson; P Whelan
Journal:  Eur Urol       Date:  1986       Impact factor: 20.096

Review 3.  What's new in tumor markers for prostate cancer?

Authors:  T M Chu; G P Murphy
Journal:  Urology       Date:  1986-06       Impact factor: 2.649

4.  [Clinical relevance of radioimmunologic determination of prostate specific antigen in prostate cancer].

Authors:  P Fornara; W Sturm; P G Fabricius; E Schmiedt
Journal:  Urologe A       Date:  1987-05       Impact factor: 0.639

5.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.

Authors:  T A Stamey; N Yang; A R Hay; J E McNeal; F S Freiha; E Redwine
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

6.  Relative reliability of five serially measured markers for prognosis of progression in prostate cancer.

Authors:  C S Killian; L J Emrich; F P Vargas; N Yang; M C Wang; R L Priore; G P Murphy; T M Chu
Journal:  J Natl Cancer Inst       Date:  1986-02       Impact factor: 13.506

7.  Immunochemical evaluation of the organ specificity of prostatic acid phosphatase.

Authors:  L M Shaw; N Yang; J J Brooks; M Neat; E Marsh; B Seamonds
Journal:  Clin Chem       Date:  1981-09       Impact factor: 8.327

8.  Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay.

Authors:  M Kuriyama; M C Wang; L D Papsidero; C S Killian; T Shimano; L Valenzuela; T Nishiura; G P Murphy; T M Chu
Journal:  Cancer Res       Date:  1980-12       Impact factor: 12.701

9.  Purification of a human prostate specific antigen.

Authors:  M C Wang; L A Valenzuela; G P Murphy; T M Chu
Journal:  Invest Urol       Date:  1979-09

10.  Evaluation of prostate-specific antigen and prostatic acid phosphatase as prostate cancer markers.

Authors:  B Seamonds; N Yang; K Anderson; B Whitaker; L M Shaw; J R Bollinger
Journal:  Urology       Date:  1986-12       Impact factor: 2.649
  10 in total
  1 in total

1.  Preoperative staging and early postoperative complications in radical prostatectomy. Experiences in 35 cases.

Authors:  I Romics; D Bach; T Widmann
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.